Today’s Research Reports on Trending Tickers: Array BioPharma and Nektar Therapeutics
NEW YORK, NY / ACCESSWIRE / January 10, 2018 / U.S. markets continued to climb to new record highs as we enter into earnings season. Major financial companies, BlackRock, J.P. Morgan Chase and Wells Fargo, are set to report quarterly earnings this week. Profits of the S&P 500 are forecasted to increase by 11.8 percent in the fourth quarter, up from an 8 percent rise a year ago, according to Thomson Reuters I/B/E/S.
The S&P 500 Index gained 0.13 percent to close at 2,751.29, while the Nasdaq Composite Index rose 0.09 percent to close at 7,163.58. This marked the 6th consecutive close for both the Nasdaq and S&P 500 in 2018, the longest streak to begin a year since 1987. The Dow Jones Industrial Average increased 0.41 percent to close at 25,385.80.
RDI Initiates Coverage on:
Array BioPharma Inc.
https://rdinvesting.com/news/?ticker=ARRY
Nektar Therapeutics
https://rdinvesting.com/news/?ticker=NKTR
Array BioPharma's stock jumped 7.63% Tuesday, to close the day at $13.55. The stock recorded a trading volume of 5,807,546 shares, which was above its three months average volume of 3,022,966 shares. In the last year Array BioPharma's shares have traded in a range of 6.73 - 14.13. The share price has gained 101.34% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $11.65 is greater than its 200-day moving average of $10.36. Shares of Array BioPharma have gained roughly 20.44 percent in the past month and are up 5.86 percent year-to-date.
Access RDI's Array BioPharma Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ARRY
On Tuesday, shares of Nektar Therapeutics recorded a trading volume of 5,986,572 shares, which was above the three months average volume of 2,310,107 shares. The stock ended the day 18.52% higher at 68.03. The share price has gained 496.23% from its 52 week low with a 52 week trading range of 11.41 - 69.42. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $55.14 is greater than its 200-day moving average of $30.69. Shares of Nektar Therapeutics have gained roughly 26.05 percent in the past month and are up 13.91 percent year-to-date.
Access RDI's Nektar Therapeutics Research Report at:
https://rdinvesting.com/news/?ticker=NKTR
Our Actionable Research on Array BioPharma Inc. (NASDAQ:ARRY) and Nektar Therapeutics (NASDAQ:NKTR) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
